These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 7716703)

  • 21. Cytokines in systemic lupus erythematosus.
    Poole BD; Niewold TB; Tsokos GC; Via CS
    J Biomed Biotechnol; 2010; 2010():735169. PubMed ID: 21603232
    [No Abstract]   [Full Text] [Related]  

  • 22. Cytokines and their receptors as biomarkers of systemic lupus erythematosus.
    Suh CH; Kim HA
    Expert Rev Mol Diagn; 2008 Mar; 8(2):189-98. PubMed ID: 18366305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic lupus erythematosus: immunopathogenesis of neurologic dysfunction.
    Moore PM; Lisak RP
    Springer Semin Immunopathol; 1995; 17(1):43-60. PubMed ID: 7482226
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumour necrosis factor and other cytokines in murine lupus.
    Theofilopoulos AN; Lawson BR
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I49-55. PubMed ID: 10577973
    [No Abstract]   [Full Text] [Related]  

  • 25. T helper cell subsets in the pathogenesis of systemic lupus erythematosus.
    Reininger L; Santiago ML; Takahashi S; Fossati L; Izui S
    Ann Med Interne (Paris); 1996; 147(7):467-71. PubMed ID: 9092356
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA as a marker of cell death in systemic lupus erythematosus.
    Pisetsky DS
    Rheum Dis Clin North Am; 2004 Aug; 30(3):575-87, x. PubMed ID: 15261342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Physiopathology of systemic lupus erythematosus: a 2014 update].
    Mathian A; Arnaud L; Amoura Z
    Rev Med Interne; 2014 Aug; 35(8):503-11. PubMed ID: 24262408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced immune system activation and arterial inflammation accelerates atherosclerosis in lupus-prone mice.
    Gautier EL; Huby T; Ouzilleau B; Doucet C; Saint-Charles F; Gremy G; Chapman MJ; Lesnik P
    Arterioscler Thromb Vasc Biol; 2007 Jul; 27(7):1625-31. PubMed ID: 17446440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity.
    Talaat RM; Mohamed SF; Bassyouni IH; Raouf AA
    Cytokine; 2015 Apr; 72(2):146-53. PubMed ID: 25647269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus.
    Cross JT; Benton HP
    Inflamm Res; 1999 May; 48(5):255-61. PubMed ID: 10391113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New biologic therapy for systemic lupus erythematosus.
    Ding HJ; Gordon C
    Curr Opin Pharmacol; 2013 Jun; 13(3):405-12. PubMed ID: 23664092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytokines and systemic lupus erythematosus.
    Dean GS; Tyrrell-Price J; Crawley E; Isenberg DA
    Ann Rheum Dis; 2000 Apr; 59(4):243-51. PubMed ID: 10733469
    [No Abstract]   [Full Text] [Related]  

  • 33. Systemic lupus erythematosus and atherosclerosis: Review of the literature.
    Frieri M; Stampfl H
    Autoimmun Rev; 2016 Jan; 15(1):16-21. PubMed ID: 26299985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
    Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
    J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticytokine therapy in systemic lupus erythematosus.
    Yoo DH
    Lupus; 2010 Oct; 19(12):1460-7. PubMed ID: 20947558
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of heart rate variability, a marker for cardiac health, on lupus disease activity.
    Thanou A; Stavrakis S; Dyer JW; Munroe ME; James JA; Merrill JT
    Arthritis Res Ther; 2016 Sep; 18(1):197. PubMed ID: 27590046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of inflammatory markers associated with systemic lupus erythematosus patients undergoing treatment.
    Timóteo RP; Micheli DC; Teodoro RB; Freire M; Bertoncello D; Murta EF; Tavares-Murta BM
    Rev Bras Reumatol Engl Ed; 2016; 56(6):497-503. PubMed ID: 27914596
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of inflammation in cancer and systemic lupus erythematosus.
    Rinaldi I
    Acta Med Indones; 2013 Jul; 45(3):167-9. PubMed ID: 24045384
    [No Abstract]   [Full Text] [Related]  

  • 39. Methyl salicylate 2-
    He YY; Yan Y; Zhang HF; Lin YH; Chen YC; Yan Y; Wu P; Fang JS; Yang SH; Du GH
    Drug Des Devel Ther; 2016; 10():3183-3196. PubMed ID: 27729775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphocytes, cytokines, inflammation, and immune trafficking.
    Tsokos GC; Kovacs B; Liossis SN
    Curr Opin Rheumatol; 1997 Sep; 9(5):380-6. PubMed ID: 9309192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.